Hence, re-examination of this issue using an EAE immunisation protocol that uses an adjuvant (e.g., Quil A) that does not itself produce neuroinflammation [47,123] is warranted to assess the extent to which NGF has a role in the pathobiology of MS-associated neuropathic pain. This evidence concerns the gene NGF and myeloid sarcoma.